This Request for Proposals (RFP) is for initiatives that span multiple rare disease areas. The National Medical Assocation (NMA) and Pfizer Global Medical Grants (GMG) are collaborating to offer a new competitive grant opportunity focused on supporting Quality Improvement projects which address significant barriers that contribute to geographic and racial healthcare disparities disproportionately impacting minority populations potentially affected by Cardiac Amyloidosis.

It is Pfizer's intent to support independent Quality Improvement (QI) initiatives which focus on one or both of the following:

• Identify significant barriers that contribute to geographic and racial healthcare disparities disproportionately impacting minority populations potentially affected by Cardiac Amyloidosis (inclusive of hereditary transthyretin amyloid cardiomyopathy) and addressing these challenges to increase earlier diagnosis, quality care and improved patient outcomes through innovative and sustainable approaches.

AND/OR

• Improve and help advance already established coordinated partnerships with local organizations (e.g., religious groups, local businesses) and local community healthcare centers to better address at least one social determinant of health (SDoH) and signs and symptoms of potential cardiac amyloidosis.

All projects ultimately supported must have a focus on data collection and analysis, specifically how the changes and improvements will be measured. The measurements should be tailored to the individual project and the specific data collection capabilities of the grantee.

Proposals coming from community engaged programs such as academic community partnerships and local community organizations (barber shops, beauty salons, religious groups, non-profit organizations, etc.) are encouraged and will be prioritized.

Estimated Total Program Funding: